Today it was reported that the CORPVP,CHIEFSCIENTIFIC OFFICER of Integra Lifesciences (IART), Kenneth Burhop, exercised options to sell 6,656 IART shares at $29.61 a share, for a total transaction value of $425.8K.
In addition to Kenneth Burhop, 2 other IART executives reported Sell trades in the last month.
See today’s analyst top recommended stocks >>
Based on Integra Lifesciences’ latest earnings report for the quarter ending June 30, the company posted quarterly revenue of $384 million and quarterly net profit of $29.74 million. In comparison, last year the company earned revenue of $366 million and had a net profit of $11.38 million. IART’s market cap is $5.52B and the company has a P/E ratio of 55.21. Currently, Integra Lifesciences has an average volume of 399.9K.
One of the top 25 analysts, according to TipRanks.com, recently recommended Buy IART with a $69 price target. Based on 6 analyst ratings, the analyst consensus is Moderate Buy with an average price target of $69.67, reflecting a 9.9% upside.
The insider sentiment on Integra Lifesciences has been negative according to 65 insider trades in the past three months. This sentiment is lower than the average sentiment of company insiders in this sector.
Company insider trades are published daily on the SEC (Securities and Exchange Commission). DailyInsider’s proprietary algorithm analyzes these trades and selects the most attractive stocks based on influential insider trades each day. To subscribe to the DailyInsider visit this page.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Integra LifeSciences Holdings Corp. engages in the manufacture and sale of medical instruments, devices, and equipment. It operates through the Codman Specialty Surgical, and Orthopedics and Tissue Technologies segments.
